Protein biosynthesis

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

Retrieved on: 
Thursday, July 29, 2021
Protein biosynthesis, Autoimmune diseases, Lung disorders, Branches of biology, Histidine—tRNA ligase, Transfer RNA, Biology, Aminoacyl tRNA synthetase, Sarcoidosis, Chemistry, aTyr Pharma, Xiang-Lei Yang

11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.

Key Points: 
  • 11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.
  • ATYR1923 is a Fc fusion protein based on the N terminal fragment of histidyl-tRNA synthetase that is currently in clinical development for the treatment of pulmonary sarcoidosis and is being evaluated in other inflammatory lung diseases.
  • These patents encompassed important new therapeutic modalities which underpin the broad pipeline of novel therapeutics in active development at the company.
  • aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases.

Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Biology, Life sciences, Commodore 64, KERNAL, RNA, Protein biosynthesis, Messenger RNA

According to Co-founder and Chief Executive Officer Yusuf Erkul, M.D., the company has recruited a powerhouse team, which has enabled Kernal Bio to meet key scientific milestones.

Key Points: 
  • According to Co-founder and Chief Executive Officer Yusuf Erkul, M.D., the company has recruited a powerhouse team, which has enabled Kernal Bio to meet key scientific milestones.
  • A silver lining to the global pandemic has been the tremendous interest in companies like Kernal Bio because of all the excitement surrounding mRNA technologies.
  • One of the first questions we are typically asked is how Kernal Bios approach differs from other well-known mRNA companies, said Dr. Erkul.
  • The critical differentiator is the combination of powerful encryption and onco-selectivity that comprises Kernal Bios mRNA technology.

Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology

Retrieved on: 
Wednesday, July 21, 2021
Nucleic acids, Branches of biology, Biology, RNA, DNA, Gene expression, Molecular genetics, Protein biosynthesis, Messenger RNA, Gibson assembly

Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system as well as within the companys BioFoundry Services offering.

Key Points: 
  • Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system as well as within the companys BioFoundry Services offering.
  • Codex DNAs new BioXp small-scale mRNA synthesis kit with CleanCap reagents is expected to overcome many of these challenges by increasing the yields and productivity of synthetically designed mRNA products.
  • The TriLink CleanCap technology is the current industry standard for capping mRNA and this collaboration enables us to expand the range of applications for our award-winning BioXp system, said Todd R. Nelson, PhD, CEO of Codex DNA.
  • Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are trademarks of Codex DNA Inc.

Molecules in motion: researchers capture six new structures of the ribosome in action

Retrieved on: 
Thursday, July 8, 2021
Nucleic acids, RNA, Branches of biology, Protein biosynthesis, RNA splicing, Molecular biology, Ribozymes, Ribosome

The ribosome is the cellular organelle responsible for decoding messenger RNA to make proteins.

Key Points: 
  • The ribosome is the cellular organelle responsible for decoding messenger RNA to make proteins.
  • Many antibiotics target the ribosome; therefore, a better understanding of how it works has important implications for drug development.
  • "A fundamental question in science is how molecules harness thermal and chemical energy to perform their diverse functions," said corresponding author Scott Blanchard , Ph.D., St. Jude Structural Biology.
  • "One of the real mysteries of life is figuring out how molecules navigate between various conformations, in an ordered way, to generate directional motion and work."

Dave Johnson Joins Biosplice Therapeutics Board of Directors

Retrieved on: 
Monday, June 21, 2021
Life sciences, Branches of biology, Biotechnology, Gene expression, Messenger RNA, Protein biosynthesis, RNA, Spliceosome, Regulus Therapeutics, United Therapeutics

SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.

Key Points: 
  • SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.
  • Dave Johnson brings more than 25 years of biopharmaceutical experience.
  • Mr. Johnson also currently serves as Chairman of Aura Biosciences, Inc. and as a director of Zentalis Pharmaceuticals (NASDAQ: ZNTL).
  • Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.

Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Retrieved on: 
Thursday, May 13, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, New York City, Biology, Gene expression, Messenger RNA, Protein biosynthesis, RNA, Spliceosome, BioScience, Brooklyn

Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited.

Key Points: 
  • Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited.
  • His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many other publications.
  • In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.
  • Forward-looking statements are made based on information available to Brooklyn on the date of this press release, and Brooklyn assumes no obligation to update the information contained in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005303/en/\n'

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

b'aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • b'aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyr\xe2\x80\x99s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Anima Biotech to Present at the Undruggable Leaders Forum Europe

Retrieved on: 
Thursday, April 8, 2021
Branches of biology, Biology, Biochemistry, Gene expression, Protein biosynthesis, RNA, Molecular biology, Drug discovery, Messenger RNA, Anima, Translation, Druggability

BERNARDSVILLE, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced that the company will be giving a live presentation during the Undruggable Leaders Forum Europe, between Apr.

Key Points: 
  • BERNARDSVILLE, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced that the company will be giving a live presentation during the Undruggable Leaders Forum Europe, between Apr.
  • During the virtual meeting, Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, and Iris Alroy, Ph.D., Vice President of Research and Development at the company, will give a company presentation highlighting Animas Translation Control Therapeutics technology and multiple programs under development.
  • Details regarding the presentation are as follows:
    Anima Biotech is pioneering Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins.
  • Our science was further validated with seven patents, 15 peer reviewed publications and 17 scientific collaborations.

Sodium Fusidate Oral: A Bacterial Protein Synthesis Inhibitor by Preventing the Turnover Ofelongation Factor G (EF-G) from the Ribosome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 7, 2021
Health, Pharmaceutical, Chemistry, Protein biosynthesis, Physical sciences, Branches of biology, Diols, Fusidic acid, Desiccants, Protein synthesis inhibitor, EF-G, Sodium, Elongation factor

"SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.

Key Points: 
  • "SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Sodium Fusidate oral, (also known as Fusidic acid, FA or sodium fusidate) acts as a bacterial protein synthesis inhibitor by preventing the turnover ofelongation factor G (EF-G) from the ribosome.
  • What are the other emerging products available and how these are giving competition to SODIUM FUSIDATE ORAL?